Skip to main content

Table 2 Overview of the computed patient characteristic distributions from our EHR structured data in comparison to the original study

From: Feasibility analysis of conducting observational studies with the electronic health record

DPS study
Patient characteristics Publication (P) EHR (E)
  DP: 1956–2006 (50 years)
n = 2919
DP: Nov 1999 – Sep 2016 (17 years)
n = 411
Demography Sex Male, n (%) 2579 (88.4) 327 (79.6)
Female, n (%) 340 (11.6) 84 (20.4)
Mean age Male, years 57.62 61.39
Female, years 62.62 64.57
Complications Nerve injury, n (%) 108 (3.7) 3 (0.73)
Tendon injury, n (%) 5 (0.2) 2 (0.49)
Skin necrosis, n (%) 76 (2.6) 0 (0)
Infection, n (%) 94 (3.2) 1 (0.24)
Bleeding, n (%) 35 (1.2) 7 (1.7)
Comorbidities Diabetes mellitus, n (%) 306 (10.5) 25 (6.1)
Epilepsy, n (%) 39 (1.3) 5 (1.2)
  DP: 1988–2006 (18 years)
n = 1119
DP: Nov 1999 – Sep 2016 (17 years)
n = 411
Demography Sex Male, n (%) 977 (87.3) 327 (79.6)
Female, n (%) 142 (12.7) 84 (20.4)
Affected digit/s One digit, n (%) 505 (45.1) 100 (24.3)
More than one digit, n (%) 614 (54.9) 263 (64)
Operation technique Limited fasciectomy, n (%) 1061 (94.8) 5 (1.2)
Total fasciectomy, n (%) 58 (5.2) 0 (0)
Additional amputation, n (%) 13 (1.2) 2 (0.5)
Recurrence, n (%) 145 (13) 67 (16.3)
Lifestyle Smoking, n (%) 185 (16.5) 11 (2.7)
Alcohol, n (%) 236 (21.1) 4 (1)
Both, n (%) 76 (6.8) 0 (0)
Simultaneous operations Carpal tunnel, n (%) 14 (1.3) 33 (8.0)
Trigger finger, n (%) 26 (2.3) 44 (10.7)
DG study
Patient characteristics Publication (P) EHR (E)
  DP: Jan 2002 – Dec 2011 (9 years)
n = 368
DP: Dec 2000 – Sep 2016 (15 years)
n = 423
Demography Sex Male, n (%) 269 (73.1) 297 (70.2)
Female, n (%) 99 (26.9) 126 (29.8)
Mean Age Total, years (range) 61.3 (21–94) 62.5 (19–96)
Balloon Dilatation, years 61.8 57.7
Bougination, years 63.4 63.5
Balloon dilatation,
Bougination
Patient with balloon dilatation, n (%) 68 (18.5) 69 (16.3)
Patient with bougination, n (%) 300 (81.5) 354 (83.7)
Sessions of balloon dilatation, n 211 136
Sessions of bougination, n 1286 1281
Total sessions, n 1497 (4.07 per patient) 1417 (3.35 per patient)
Perforation Balloon dilatations, n 0 0
Bougination, n 8 5
Occurence, n During first session: 4
During second session: 4
During first session: 3
During second session: 1
During later sessions: 1
Detection, n During procedure: 4
After procedure: 4
No specification: 5
Rate per procedure, % 0.53 0.35
Rate per patient, % 2.17 1.18
Death, n 1 0
Length of hospital stay With perforation, days (range) 21.3 (9–41) 19.2 (4–36)
Without perforation, days (range) 6.8 (2–13) 9.1 (1–80)
DRO Study
Patient characteristics Publication (P) EHR (E)
  DP: unknown
Gemcitabine and cisplatin
n = 58
DP: Jan 2008 – May 2015
Gemcitabine and cisplatin
n = 13
Demography Sex Male, n (%) 36 (62) 10 (76.9)
Female, n (%) 22 (38) 3 (23.1)
Mean Age, years 63 60.5
Tumor Location Head, n (%) 40 (69) 6 (46.2) 3 (23.1) (no specification)
Body, n (%) 9 (16) 1 (7.7)
Tail, n (%) 1 (2) 0 (0)
Head body, n (%) 5(9) 3 (23.1)
Body tail, n (%) 3 (5)
Diagnosed by Biopsy, n (%) 41 (71) 1 (7.7)
Operation, n (%) 15 (29) 0 (0)
Median Duration Radiotherapy, days 42 42
Survival Alive at analysis, n 2 10
  1. Note that the DPS study included two observational periods. DP = data period